Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 16-Oct-24 6:53 PM View:  | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Oct-24 | Planned Option Sale | 10,000 | $53.26 | $532,590.00 | (5%) 183.76K to 173.76K | |
| 16-Oct-24 6:53 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 16-Oct-24 | Option Exercise | 10,000 | $19.98 | $199,800.00 | 6% 173.76K to 183.76K | |
| 16-Oct-24 6:53 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Oct-24 | Planned Option Sale | 10,000 | $53.75 | $537,469.00 | (5%) 183.76K to 173.76K | |
| 16-Oct-24 6:53 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 15-Oct-24 | Option Exercise | 10,000 | $18.15 | $181,455.00 | 6% 173.76K to 183.76K | |
| 09-Oct-24 5:39 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 09-Oct-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 09-Oct-24 5:39 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 09-Oct-24 | Planned Option Sale | 10,000 | $52.58 | $525,783.00 | (1%) 686.74K to 676.74K | |
| 09-Oct-24 5:39 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 08-Oct-24 | Planned Option Sale | 10,000 | $54.00 | $539,961.00 | (1%) 686.74K to 676.74K | |
| 09-Oct-24 5:39 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 08-Oct-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 26-Sep-24 6:06 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 26-Sep-24 | Planned Option Sale | 10,000 | $56.10 | $560,970.00 | (1%) 686.74K to 676.74K | |
| 26-Sep-24 6:06 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 26-Sep-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 26-Sep-24 6:06 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 25-Sep-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 26-Sep-24 6:06 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 25-Sep-24 | Planned Option Sale | 10,000 | $56.34 | $563,370.00 | (1%) 686.74K to 676.74K | |
| 26-Sep-24 6:06 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 24-Sep-24 | Planned Option Sale | 10,000 | $58.21 | $582,100.00 | (1%) 686.74K to 676.74K | |
| 26-Sep-24 6:06 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 24-Sep-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 18-Sep-24 6:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 18-Sep-24 | Planned Option Sale | 10,000 | $62.03 | $620,316.00 | (5%) 183.76K to 173.76K | |
| 18-Sep-24 6:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 18-Sep-24 | Option Exercise | 10,000 | $16.65 | $166,500.00 | 6% 173.76K to 183.76K | |
| 18-Sep-24 6:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 17-Sep-24 | Option Exercise | 10,000 | $16.65 | $166,500.00 | 6% 173.76K to 183.76K | |
| 18-Sep-24 6:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 17-Sep-24 | Planned Option Sale | 10,000 | $62.88 | $628,780.00 | (5%) 183.76K to 173.76K | |
| 12-Sep-24 5:56 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 12-Sep-24 | Planned Option Sale | 10,000 | $59.20 | $592,030.00 | (1%) 686.74K to 676.74K | |
| 12-Sep-24 5:56 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 12-Sep-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 12-Sep-24 5:56 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 11-Sep-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 12-Sep-24 5:56 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 11-Sep-24 | Planned Option Sale | 10,000 | $59.09 | $590,870.00 | (1%) 686.74K to 676.74K | |
| 12-Sep-24 5:56 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 10-Sep-24 | Planned Option Sale | 10,000 | $59.09 | $590,890.00 | (1%) 686.74K to 676.74K | |
| 12-Sep-24 5:56 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 10-Sep-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 27-Aug-24 7:49 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 27-Aug-24 | Option Exercise | 5,580 | $18.41 | $102,728.00 | 3% 168.18K to 173.76K | |
| 21-Aug-24 6:03 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 21-Aug-24 | Planned Option Sale | 10,000 | $61.75 | $617,470.00 | (6%) 178.18K to 168.18K | |
| 21-Aug-24 6:03 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 21-Aug-24 | Option Exercise | 10,000 | $16.65 | $166,500.00 | 6% 168.18K to 178.18K | |
| 21-Aug-24 6:03 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 20-Aug-24 | Planned Option Sale | 10,000 | $61.06 | $610,550.00 | (6%) 178.18K to 168.18K | |
| 21-Aug-24 6:03 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 20-Aug-24 | Option Exercise | 10,000 | $16.65 | $166,500.00 | 6% 168.18K to 178.18K | |
| 15-Aug-24 4:59 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 15-Aug-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 15-Aug-24 4:59 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 15-Aug-24 | Planned Option Sale | 10,000 | $57.95 | $579,490.00 | (1%) 686.74K to 676.74K | |
| 15-Aug-24 4:59 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 14-Aug-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 15-Aug-24 4:59 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 14-Aug-24 | Planned Option Sale | 10,000 | $57.25 | $572,471.00 | (1%) 686.74K to 676.74K | |
| 14-Aug-24 4:57 PM View: | Posard Matthew L. Director | Halozyme Therapeutics, Inc. (HALO) | 14-Aug-24 | Sale | 9,881 | $57.70 | $570,134.00 | (12%) 79.75K to 69.87K | |
| 14-Aug-24 4:57 PM View: | Posard Matthew L. Director | Halozyme Therapeutics, Inc. (HALO) | 13-Aug-24 | Sale | 10,000 | $56.19 | $561,930.00 | (11%) 89.75K to 79.75K | |
| 15-Aug-24 4:59 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 13-Aug-24 | Option Exercise | 10,000 | $13.87 | $138,700.00 | 1% 676.74K to 686.74K | |
| 15-Aug-24 4:59 PM View: | Torley Helen President and CEO Director | Halozyme Therapeutics, Inc. (HALO) | 13-Aug-24 | Planned Option Sale | 10,000 | $56.25 | $562,490.00 | (1%) 686.74K to 676.74K | |
| 14-Aug-24 4:57 PM View: | Posard Matthew L. Director | Halozyme Therapeutics, Inc. (HALO) | 12-Aug-24 | Private Sale | 10,000 | $55.72 | $557,230.00 | (10%) 99.75K to 89.75K | |
| 24-Jul-24 5:48 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 24-Jul-24 | Option Exercise | 10,000 | $15.19 | $151,854.00 | 6% 168.18K to 178.18K | |
| 24-Jul-24 5:48 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 24-Jul-24 | Planned Option Sale | 10,000 | $55.12 | $551,150.00 | (6%) 178.18K to 168.18K | |
| 24-Jul-24 5:48 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 23-Jul-24 | Planned Option Sale | 10,000 | $54.89 | $548,873.00 | (6%) 178.18K to 168.18K | |
| 24-Jul-24 5:48 PM View: | Labarre Michael J. SVP, Chief Technical Officer | Halozyme Therapeutics, Inc. (HALO) | 23-Jul-24 | Option Exercise | 10,000 | $8.11 | $81,100.00 | 6% 168.18K to 178.18K | |
| 23-Jul-24 4:37 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 22-Jul-24 | Option Exercise | 5,000 | $22.50 | $112,500.00 | 32% 15.48K to 20.48K | |
| 23-Jul-24 4:37 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 22-Jul-24 | Planned Option Sale | 5,000 | $53.93 | $269,662.00 | (24%) 20.48K to 15.48K | |
| 28-Jun-24 4:06 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 28-Jun-24 | Option Exercise | 10,000 | $22.50 | $225,000.00 | 65% 15.48K to 25.48K | |
| 28-Jun-24 4:06 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 28-Jun-24 | Planned Option Sale | 10,000 | $52.04 | $520,400.00 | (39%) 25.48K to 15.48K | |
| 28-Jun-24 4:06 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 27-Jun-24 | Planned Option Sale | 10,000 | $51.93 | $519,340.00 | (39%) 25.48K to 15.48K | |
| 28-Jun-24 4:06 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 27-Jun-24 | Option Exercise | 10,000 | $22.50 | $225,000.00 | 65% 15.48K to 25.48K | |
| 28-Jun-24 4:06 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 26-Jun-24 | Option Exercise | 10,000 | $22.50 | $225,000.00 | 65% 15.48K to 25.48K | |
| 28-Jun-24 4:06 PM View: | Labrosse Nicole SVP, Chief Financial Officer | Halozyme Therapeutics, Inc. (HALO) | 26-Jun-24 | Planned Option Sale | 10,000 | $51.82 | $518,200.00 | (39%) 25.48K to 15.48K |
